Shares of Blueprint Medicines Corp. surged in its debut on the Nasdaq after the biotech company raised more cash than it expected in its initial public offering. The Cambridge, Massachusetts-based cancer drug developer sold 8.15 million shares of its common stock in an upsized offering at $18.00 per share, raising about $147 million.